Literature DB >> 14706840

Fibronectin is a hypoxia-independent target of the tumor suppressor VHL.

Hans A R Bluyssen1, Martijn P J K Lolkema, Moniek van Beest, Michelle Boone, Cristel M J T Snijckers, Maartje Los, Martijn F B G Gebbink, Branko Braam, Frank C P Holstege, Rachel H Giles, Emile E Voest.   

Abstract

The von Hippel-Lindau (VHL) tumor suppressor gene regulates the extracellular matrix by controlling fibronectin deposition. To identify novel VHL target genes, we subjected mRNA from VHL-deficient RCC cells (786-0-pRC) and a transfectant re-expressing wildtype VHL (786-0-VHL) to differential expression profiling. Among the differentially expressed genes, we detected that fibronectin is upregulated in the presence of VHL, while it is not affected by hypoxia. Thus regulation of fibronectin deposition by VHL occurs at the transcriptional level, irrespective of oxygen levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706840     DOI: 10.1016/s0014-5793(03)01392-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  22 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

2.  Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation.

Authors:  Qingzhou Ji; Robert D Burk
Journal:  Biochem Cell Biol       Date:  2008-06       Impact factor: 3.626

Review 3.  Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Mark Kidd; Irvin Modlin; Kjell Öberg
Journal:  Nat Rev Clin Oncol       Date:  2016-06-07       Impact factor: 66.675

4.  Deletion of von Hippel-Lindau in glomerular podocytes results in glomerular basement membrane thickening, ectopic subepithelial deposition of collagen {alpha}1{alpha}2{alpha}1(IV), expression of neuroglobin, and proteinuria.

Authors:  Brooke M Steenhard; Kathryn Isom; Larysa Stroganova; Patricia L St John; Adrian Zelenchuk; Paul B Freeburg; Lawrence B Holzman; Dale R Abrahamson
Journal:  Am J Pathol       Date:  2010-06-03       Impact factor: 4.307

Review 5.  Von Hippel-Lindau syndrome: molecular mechanisms of the disease.

Authors:  María J Calzada
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

6.  The p53 inhibitor pifithrin-α can stimulate fibrosis in a rat model of ischemic acute kidney injury.

Authors:  Pierre C Dagher; Erik M Mai; Takashi Hato; So-Young Lee; Melissa D Anderson; Stephanie C Karozos; Henry E Mang; Nicole L Knipe; Zoya Plotkin; Timothy A Sutton
Journal:  Am J Physiol Renal Physiol       Date:  2011-11-02

7.  Human nephrosclerosis triggers a hypoxia-related glomerulopathy.

Authors:  Matthias A Neusser; Maja T Lindenmeyer; Anton G Moll; Stephan Segerer; Ilka Edenhofer; Kontheari Sen; Daniel P Stiehl; Matthias Kretzler; Hermann-Josef Gröne; Detlef Schlöndorff; Clemens D Cohen
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

8.  Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.

Authors:  Sergey V Ivanov; Alla V Ivanova; Konstantin Salnikow; Olga Timofeeva; Malayannan Subramaniam; Michael I Lerman
Journal:  Biochem Biophys Res Commun       Date:  2008-03-24       Impact factor: 3.575

9.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

10.  Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future.

Authors:  John S P Yuen
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.